Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2023)

Historic Other financing activities for Xeris Biopharma Holdings (XERS) over the last 4 years, with Q4 2023 value amounting to $1.2 million.

  • Xeris Biopharma Holdings' Other financing activities rose 187500.0% to $1.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.2 million, marking a year-over-year decrease of 7569.73%. This contributed to the annual value of $1.2 million for FY2023, which is 7569.73% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Other financing activities stood at $1.2 million for Q4 2023, which was up 187500.0% from $60000.0 recorded in Q4 2022.
  • Xeris Biopharma Holdings' Other financing activities' 5-year high stood at $4.4 million during Q1 2022, with a 5-year trough of $54000.0 in Q2 2021.
  • Moreover, its 4-year median value for Other financing activities was $159000.0 (2022), whereas its average is $881714.3.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Other financing activities skyrocketed by 45000.0% in 2022 and then soared by 187500.0% in 2023.
  • Quarter analysis of 4 years shows Xeris Biopharma Holdings' Other financing activities stood at $57000.0 in 2020, then dropped by 5.26% to $54000.0 in 2021, then increased by 11.11% to $60000.0 in 2022, then surged by 1875.0% to $1.2 million in 2023.
  • Its Other financing activities stands at $1.2 million for Q4 2023, versus $60000.0 for Q4 2022 and $159000.0 for Q3 2022.